Only two injections a year, the latest phase 3 clinical data show that Gilead's long-acting HIV therapy has a long-lasting effect

A few days ago, Gilead Sciences announced at the 11th International AIDS Society (IAS) conference the latest results of its ongoing research on the long-acting HIV-1 capsid inhibitor lenacapavir in the Phase 2/3 clinical trial CAPELLA

Lenacapavir is a potential "first-in-class" capsid inhibitor developed by Gilead Sciences.

The advantage of Lenacapavir is that patients may only need to receive an injection every 6 months to maintain its effectiveness

▲Introduction to Lenacapavir therapy (picture source: Gilead Sciences official website)

In addition to 81% of CAPELLA test subjects reaching an undetectable viral load level at week 26, the subjects’ CD4-positive T cell technology increased by an average of 81 cells/μl

In addition, Gilead also announced the Phase 2 clinical trial of lenacapavir orally or subcutaneously in combination with oral emtricitabine/tenofovir alafenamide (F/TAF) for the treatment of newly-treated HIV-1 infected patients.

Note: The original text has been deleted

Reference materials:

[1] New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor.